148 related articles for article (PubMed ID: 31794609)
1. Exploring the Potential of CAR-T Therapy for Heart Failure.
Hampton T
JAMA; 2019 Dec; 322(21):2066-2067. PubMed ID: 31794609
[No Abstract] [Full Text] [Related]
2. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
3. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
5. The Promise and Challenges of CAR-T Gene Therapy.
Kuehn BM
JAMA; 2017 Dec; 318(22):2167-2169. PubMed ID: 29167891
[No Abstract] [Full Text] [Related]
6. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
7. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
8. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C; Locatelli F; Caruana I; De Angelis B
Mol Ther; 2016 May; 24(5):845-6. PubMed ID: 27198849
[No Abstract] [Full Text] [Related]
10. Sending CAR T Cells After Multiple Myeloma.
Cancer Discov; 2017 Aug; 7(8):OF9. PubMed ID: 28588060
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
12. From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction.
Sadelain M
Cancer J; 2014; 20(2):105-6. PubMed ID: 24667953
[No Abstract] [Full Text] [Related]
13. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Prasad V
Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930
[No Abstract] [Full Text] [Related]
14. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
Avanzi MP; Brentjens RJ
J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
[TBL] [Abstract][Full Text] [Related]
15. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
16. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
Wang J; Zhou P
Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
[TBL] [Abstract][Full Text] [Related]
17. Driving T-cell immunotherapy to solid tumors.
Garber K
Nat Biotechnol; 2018 Mar; 36(3):215-219. PubMed ID: 29509745
[No Abstract] [Full Text] [Related]
18. CAR-T in the clinic: drive with care.
Yáñez-Muñoz RJ; Grupp SA
Gene Ther; 2018 Jun; 25(3):157-161. PubMed ID: 29961080
[No Abstract] [Full Text] [Related]
19. Relapses After CAR-T Therapy.
Abbasi J
JAMA; 2018 Nov; 320(18):1850. PubMed ID: 30422179
[No Abstract] [Full Text] [Related]
20. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy.
Geiger TL; Jyothi MD
Transfus Med Rev; 2001 Jan; 15(1):21-34. PubMed ID: 11149976
[No Abstract] [Full Text] [Related]
[Next] [New Search]